The results described above indicated that HAS3 and its enzymatic product HA in stroma ECM of breast tissues might attenuate breast cancer cell invasion by arresting early stage breast cancer (ductal carcinoma in situ, DCIS) cell growth at the G2/M phase cell cycle. Here, HAS3 is linked to ductal breast carcinoma in situ.